ADVAGRAF
As listed in the register: ADVAGRAF 1 MG CAPSULAS DURAS DE LIBERACION PROLONGADA
1 mg Tacrolimus · cápsula dura de liberación prolongada
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Tacrolimus
- Made by
- Astellas Pharma Europe B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Tacrolimus). It describes the substance, not this exact product.
Tacrolimus binds to an intracellular protein, FKBP-12.
A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is inhibited.
Tacrolimus is extensively metabolized by the mixed-function oxidase system, primarily the cytochrome P-450 system (CYP3A4 and CYP3A5).
In man, less than 1% of the dose administered is excreted unchanged in urine.
Food Effects The rate and extent of tacrolimus absorption were greatest under fasted conditions.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-16
Safety of the active substance
From the US prescribing label for the same active substance (Tacrolimus). It describes the substance, not this exact product.
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with tacrolimus or other immunosuppressants that may lead to hospitalization or death.
- Hypersensitivity to tacrolimus or HCO-60 (polyoxyl 60 hydrogenated castor oil).
- ( 4 ) Tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus.
- Tacrolimus injection is contraindicated in patients with a hypersensitivity to HCO-60 (polyoxyl 60 hydrogenated castor oil).
- Hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see Adverse Reactions ( 6 )].
The most common adverse reactions (≥ 15%) were abnormal renal function, hypertension, diabetes mellitus, fever, CMV infection, tremor, hyperglycemia, leukopenia, infection, anemia, bronchitis, pericardial effusion, urinary tract infection, constipation, diarrhea, headache, abdominal pain, insomnia, paresthesia, peripheral edema, nausea, hyperkalemia, hypomagnesemia, and hyperlipemia.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Canada7 matching products
- ACH-TACROLIMUS 1 mg · capsule (immediate-release)
- ADVAGRAF 1 mg · capsule (extended-release)
- APO-TACROLIMUS 1 mg · capsule (immediate-release)
- APO-TACROLIMUS CAPSULES 1 mg · capsule (immediate-release)
- PROGRAF 1 mg · capsule
- SANDOZ TACROLIMUS 1 mg · capsule (immediate-release)
- SANDOZ TACROLIMUS XR 1 mg · capsule (extended-release)
Netherlands19 matching products
- Prograft 1 mg capsules 1 mg · capsule, hard6 makers
- Adport 1 mg 1 mg · capsule, hard2 makers
- Prograft 1 mg 1 mg · capsule, hard2 makers
- Advagraf 1 mg 1 mg · capsule met verlengde afgifte, hard
- Conferoport 1 mg 1 mg · capsule met verlengde afgifte, hard
- Dailiport 1 mg 1 mg · capsule met verlengde afgifte, hard
- Prograft 1 mg harde capsules 1 mg · capsule, hard
- Tacforius 1 mg 1 mg · capsule met verlengde afgifte, hard
SwitzerlandNo exact match for this strength and form
Details
| Made by | Astellas Pharma Europe B.V. |
|---|---|
| Active substance | Tacrolimus |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 1 mg Tacrolimus |
| Form | cápsula dura de liberación prolongada |
| Classification | L04AD02 · Cancer treatments and immune-system medicines |
| Route | vía oral |
| Marketed | Yes, according to the register |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | ADVAGRAF 1 MG CAPSULAS DURAS DE LIBERACION PROLONGADA |
| Nº Registro | 07387019 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- cápsula dura de liberación prolongada5 products
- 0,5 mg Tacrolimus
1 mg Tacrolimus2
1 mg Tacrolimus · 2 companies
- Astellas Pharma Europe B.V. · this page
- Astellas Pharma Europe B.V.
- 3 mg Tacrolimus
- 5 mg Tacrolimus
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.